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background: interpatient variability in anthracycline(ANT)metabolism may contribute to the development of cardiotoxicity(CTX).Aim of the study:to 
verify the role of genetic variants of enzymes involved in drug metabolism to predict ANT-induced CTX risk in patients(pts)with non metastatic breast 
Cancer(BC).
Methods: all consecutive pts that undergo ANT treatment(Epirubicin 90mg/m2;3-4 cycles every 21days) without known heart disease are 
included in the study protocol.Genomic DNA is extracted from blood using QIAamp DNA purification system.DNA samples from pts are genotyped 
for single-nucleotide polymorphisms by TaqMan®SNP genotyping assay,which was designed to detect variants of a single nucleic acid sequence.
The presence of 2probes in each reaction allows genotyping of the 3possible variants at the SNPs site in the target sequence.Cardiac evaluation 
and measurement of cTnI and NT-proBNP are performed at baseline and 1week after each ANTcycle.For analyzing NT-proBNP behavior during ANT 
treatment,we calculated the critical difference(CD)between baseline and peak value:CD=K∙√CVa2+CVi2;CVa=coefficient of analytical variation(in 
our Lab 1.65%);CVi=coefficient of within subject variation(for NT-proBNP=35%)and K=factor dependent on the probability level selected(for 
p<.05,K=2.77).We considered significant only an increase in NT-proBNPlevel≥96%relative to baseline.
results: this preliminary analysis includes 56pts.According to NT-proBNP behavior,pts were divided into 2 groups:group1(n=19;33.93%)with a 
significant increase in NT-proBNP level,and group2(n=37;66.07%)with no significant increase.Clinical,laboratory,ECG and Echo parameters collected 
at baseline non significantly differed between the groups.About 27%of pts in group2 has the variant of rs4148808[C/T]considered protective for 
ANT-induced CTX,while no pts in the group1 has this SNPs(p<.01).
conclusions: the protective variant of rs4148808[C/T]for ABCB4 is absent in pts with significant increase in NT-proBNP during ANT treatment.The 
meaning of these findings in predicting individual susceptibility for delayed CTX development,will be elucidated at the end of follow-up.
